Abeona Therapeutics (NASDAQ: ABEO) CEO awarded 365,422 restricted shares

Rhea-AI Filing Summary

Abeona Therapeutics Inc. disclosed an equity grant to its Chief Executive Officer and director, Vishwas Seshadri. On January 20, 2026, he received 365,422 shares of common stock as restricted stock at a price of $0.00 per share. After this award, he beneficially owned 1,530,240 shares of Abeona common stock in total.

The restricted stock will vest in three equal installments, with one-third of the shares scheduled to vest on each of January 20, 2027, January 20, 2028, and January 20, 2029, aligning the CEO’s compensation with the company’s multi‑year performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seshadri Vishwas

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		A		365,422(1)	A	$0.00	1,530,240	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029.

	/s/ Vishwas Seshadri	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ABEO report for Vishwas Seshadri?

Abeona Therapeutics Inc. reported that Chief Executive Officer and director Vishwas Seshadri received an award of 365,422 shares of common stock as restricted stock on January 20, 2026.

At what price were the ABEO shares granted to the CEO?

The 365,422 restricted shares of Abeona common stock granted to Vishwas Seshadri had a grant price of $0.00 per share, reflecting a stock-based compensation award rather than an open‑market purchase.

How many ABEO shares does the CEO beneficially own after this transaction?

Following the restricted stock grant, Vishwas Seshadri beneficially owned 1,530,240 shares of Abeona Therapeutics Inc. common stock in total, held as a direct ownership position.

How do the CEO’s restricted ABEO shares vest over time?

The restricted stock granted to Vishwas Seshadri will vest in three equal installments: one‑third on January 20, 2027, one‑third on January 20, 2028, and one‑third on January 20, 2029.

Is the ABEO CEO also a director of the company?

Yes. The filing states that Vishwas Seshadri is both a Director and an Officer, serving as Abeona Therapeutics Inc.’s Chief Executive Officer.

Is this ABEO Form 4 filed by more than one reporting person?

No. The Form 4 indicates it is a Form filed by One Reporting Person, covering the holdings and transaction of Vishwas Seshadri only.